Ensitrelvir fumarate

CAS No.	2757470-18-9	Cat. No.	BCP46193
Name	Ensitrelvir fumarate
Synonyms	S-217622 fumarate; S 217622 fumarate; S217622 fumarate;
Formula	C26H21ClF3N9O6	M. Wt	647.96

Description	Ensitrelvir, also known as S-217622, is an antiviral drug developed by Shionogi in partnership with Hokkaido University, which acts as an orally active 3C-like protease inhibitor for the treatment of COVID-19 infection. It is taken by mouth, and has been successfully tested against the recently emerged Omicron variant. It is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM). It became the first Japanese domestic pill to treat COVID-19, third to be regulatorally approved in Japan; in February 2022.
Pathways	Microbiology/Virology
Targets	SARS CoV

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.